Movement Disorders Caused by Antipsychotic Drugs in Older Patients

This study has been completed.

Sponsor:

Collaborator:

National Institute of Mental Health (NIMH)

Information provided by (Responsible Party):

Dilip V. Jeste, University of California, San Diego

ClinicalTrials.gov Identifier:

NCT00255879

First received: November 16, 2005

Last updated: June 5, 2013

Last verified: November 2005

History of Changes

Purpose

This study will assess the risk of experiencing tardive dyskinesia and other movement disturbances associated with three atypical antipsychotic drugs among middle-aged and elderly psychiatric patients.

Condition	Intervention	Phase
Dyskinesia, Drug-Induced	Drug: Quetiapine Drug: Risperidone Drug: Olanzapine	Phase 1


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Neuroleptic Induced Movement Disorders in Older Patients

Resource links provided by NLM:

MedlinePlus related topics: Movement Disorders

Genetic and Rare Diseases Information Center resources: Neurotoxicity Syndromes

U.S. FDA Resources

Further study details as provided by Dilip V. Jeste, University of California, San Diego:

Primary Outcome Measures:

Extrapyramidal symptoms; measured at Months 1 and 3 and every 3 months for the remainder of the study
Tardive dyskinesia; measured at Months 1 and 3 and every 3 months for the remainder of the study

Secondary Outcome Measures:

Everyday functioning; measured at Months 1 and 3 and every 3 months for the remainder of the study
Quality of life; measured at Months 1 and 3 and every 3 months for the remainder of the study


Estimated Enrollment:	250
Study Start Date:	January 1999
Study Completion Date:	August 2004
Primary Completion Date:	August 2004 (Final data collection date for primary outcome measure)

Detailed Description:

Use of antipsychotic drugs can result in tardive dyskinesia and extrapyramidal symptoms. Tardive dyskinesia (TD) is a syndrome that causes repetitive, involuntary, purposeless movements in the tongue, lips, or jaw. It can also cause facial grimacing, random movements of arms, legs, fingers, and toes, as well as swaying movements of the trunk or hips. Extrapyramidal symptoms (EPS) include a variety of symptoms, such as involuntary movements, tremors, rigidity, body restlessness, and changes in breathing and heart rate. TD and EPS are side effects of older antipsychotic drugs. Newer antipsychotic drugs, such as quetiapine, olanzapine, and risperidone, do not present as large a risk of developing these side effects. This study will assess the incidence of and risk factors for tardive dyskinesia and extrapyramidal symptoms associated with quetiapine, olanzapine, and risperidone among middle-aged and elderly individuals with psychotic disorders. Additionally, the study will examine the effect of these drugs on symptoms of pre-existing, drug-induced TD. It will also explore the impact of movement disorder symptoms on everyday functioning and quality of life.

Some participants in this open-label study will be randomly assigned to receive quetiapine, olanzapine, or risperidone. Participants who are not randomly assigned to a medication will still receive one of the three medications, based on the decision of their physician. Initial evaluations will be conducted to collect demographic information, as well as medical, psychiatric, and pharmacologic histories. Dosing will be determined by each participant's psychiatrist. All participants will be followed for approximately 5 years. They will report to the study site for outcome assessments at baseline, Months 1 and 3, and every 3 months for the remainder of the study.

Eligibility


Ages Eligible for Study:	40 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

DSM-IV diagnosis of any psychiatric disorder for which an antipsychotic medication is needed

Exclusion Criteria:

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00255879

Locations


United States, California
University of California, San Diego Division of Geriatric Psychiatry
San Diego, California, United States, 92161

Sponsors and Collaborators

University of California, San Diego

National Institute of Mental Health (NIMH)

Investigators


Principal Investigator:	Dilip V. Jeste, MD	University of California, San Diego

More Information


Responsible Party:	Dilip V. Jeste, Professor, University of California, San Diego
ClinicalTrials.gov Identifier:	NCT00255879 History of Changes
Other Study ID Numbers:	R01MH059101 ( US NIH Grant/Contract Award Number )
Study First Received:	November 16, 2005
Last Updated:	June 5, 2013

Keywords provided by Dilip V. Jeste, University of California, San Diego:


Schizophrenia Neuroleptic Tardive dyskinesia

Additional relevant MeSH terms:


Movement Disorders Dyskinesias Dyskinesia, Drug-Induced Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Signs and Symptoms Neurotoxicity Syndromes Drug-Related Side Effects and Adverse Reactions Chemically-Induced Disorders Poisoning Antipsychotic Agents Quetiapine Fumarate Olanzapine Risperidone	Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Psychotropic Drugs Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Serotonin Antagonists

ClinicalTrials.gov processed this record on June 23, 2017

To Top